Sarepta shares resume trading, shares fall further, down 33%

Sarepta shares resume trading, shares fall further, down 33%

Sarepta Therapeutics Inc (SRPT) shares resumed trading on July 2, 2025, after a period of suspension. The stock opened at $112.74 and experienced a significant drop, closing at $75.45, representing a 33% decline from the previous session's close. The fall in price was largely driven by market sentiment and analysts' concerns about the company's recent financial performance and regulatory risks.

Investors were closely monitoring Sarepta's progress in gene therapy treatments for rare diseases, particularly the EXONDYS 51 injection and VYONDYS 53. However, the company faced challenges with its drug approvals and clinical trial results, which contributed to the stock's volatility.

Analysts from various financial institutions, such as Deutsche Bank and BMO Capital Markets, have revised their earnings expectations and price targets for Sarepta. Deutsche Bank initiated coverage on the stock, assigning a Hold rating with a price target of $136.00 [1]. BMO Capital Markets maintained an Outperform rating with a $200.00 price target, but recent developments have led to a reevaluation of the company's prospects [2].

The company's SWOT analysis highlights its strengths in precision genetic medicines and its leadership in gene therapy, but also notes significant risks, including regulatory uncertainties and competition in the biopharmaceutical market [3]. Sarepta's collaboration with Arrowhead Pharmaceuticals on a global licensing and collaboration agreement further adds to its market presence, but the agreement's impact on stock performance remains to be seen [4].

Investors should closely follow Sarepta's upcoming earnings report scheduled for March 4, 2025, and any new developments in its clinical trials and regulatory approvals. The stock's recent performance underscores the importance of staying informed about the company's progress and the broader market conditions affecting its valuation.

References:
[1] https://www.investing.com/equities/sarepta
[2] https://www.investing.com/equities/sarepta
[3] https://www.investing.com/equities/sarepta
[4] https://www.investing.com/equities/sarepta